News | December 16, 2014

Findings indicate that stronger signal is obtained when 3-D thresholded SPECT scan is performed rather than conventional SPECT scan; similar results may be obtained for other psychiatric disorders

Nuclear imaging, Clinical trial/study, ADHA, 3-D SPECT imaging

December 16, 2014 — A recently published study from Toronto, Canada found that patients who utilized 3-D SPECT were able to get a clearer diagnosis of ADHD, which is the most common psychiatric disorder in children and adults.

Published in the Journal of Neuropsychiatry and Clinical Neurosciences, the study used 3-D SPECT imaging, a nuclear medicine study that evaluates blood flow and activity levels in the brain. This research demonstrated that 3-D SPECT imaging is a beneficial tool for ruling in or out ADHD.

This study is important because of the way the SPECT scans were rendered. The 3-D renderings made the scans easier to read than the typical 2-D images, which required greater reading skills of the physicians. In the present study, 3-D thresholded SPECT scans gave a sensitivity of 83% in predicting which patients would have a clinical diagnosis of ADHD compared with a sensitivity of 10% for the conventional 2-D SPECT scans. A 10% sensitivity hardly makes SPECT scans useful for clinical psychiatric applications, which is why some researchers have criticized the use of traditional SPECT.

Daniel G. Amen, M.D., psychiatrist and founder of Amen Clinics, who is referenced in the published article but did not participate in this particular study, says, "This study points to a significant advancement in the care of people who suffer with ADHD and other psychiatric disorders. Until now, standard diagnoses in psychiatry are made primarily through talking to patients and looking at symptom clusters without any biological information. Psychiatry is the only medical specialty that virtually never looks at the organ it treats.”

For more information: www.neuro.psychiatryonline.org/doi/abs/10.1176/appi.neuropsych.12110280

 

Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
Feature | Radiology Business

June 24, 2024 — Well-known Chicago and worldwide philanthropist Ann Lurie, namesake of the Ann and Robert H Lurie ...

Time June 24, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
Subscribe Now